Castro-Sansores C, Guerrero-Flores A, Santos-Rivero A, Sarmiento-Coutiño C, Valencia-Serrano N, Bolaños-Caldelas E

Language: Spanish
References: 19
Page: 439-445
PDF size: 534.59 Kb.

ABSTRACT

Background: An increase in the cardiovascular risk (CVR) in patients with the HIV infection is being reported. The present paper analyzes the correlation between three different methods that consider the CVR in a group of patients with HIV infection, comparing the methods of Framingham, PROCAM and of the World Health Organization (WHO).
Material and method: A cross-sectional, comparative and descriptive study was realised. The patients were taken care in 8 specialized centers in the attention of patients with HIV infection of four states of south-east of Mexico (Chiapas, Quintana Roo, Tabasco and Yucatan). The CVR to 10 years, was considered in each subject through of the three referred methods being classified in low (‹10%), moderate (10-20%) and high (›20%) risk with the Framingham and PROCAM methods. For the WHO method the risk was classified in low (‹10%), moderate (10-20%), high (20-30%) and very high (›30%) risk.
Results: We studied 289 patients (35 (12%) women and 254 (88%) men). The average of age was of 39 (20-73) years. The time average to be diagnosed with the HIV infection was of 7±4.8 years. Two hundred thirty two patients (80%) were receiving HAART, the time average to receive HAART was of 4.5±4 years, among them, 169 (73%) received a protease inhibitor. The prevalence of patients with low, moderate and high CVR according to the method of Framingham was 84.4%, 10,7% and 4.8%, with PROCAM 93%, 3.8% and 3,1% and with the WHO 98%, 1,3% and 0.34%. Was not observed any patient with very high CVR (± 30%) with the method of the WHO.
Conclusions: When the CVR -whatever the used method- is compared with the method of Framingham, this risk was overestimate in the population of patients infected by HIV. The predictive value of these three methods on the development of cardiovascular disease still needs well to be established in the population infected by HIV. Meanwhile, the estimation of CVR in these patients will have to be taken with precaution.

REFERENCES

1. Patella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.

2. Hadigan C, Meigs JB, Wilson PWF, D’Agostino RB, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-916.

3. Dong KL, Bausserman LL, Flynn MM. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr Hum Retrovirol 1991;21:107-1133.

4. Castro-Sansores CJ, Santos-Rivero A, Lara-Perera D, González-Martínez P, y col. Hiperlipidemia e intolerancia a la glucosa en un grupo de pacientes infectados con VIH que reciben terapia antirretrovírica hiperactiva. Salud Pública Mex 2006;48:193-199.

5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

6. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med 2003;349:1993-2003.

7. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;23:625-630.

8. Santos J, Palacios R, González M, Ruiz J, Márquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). International Journal of STD & AIDS 2005;16:677-680.

9. Castro-Sansores C, Santos-Rivero A, Guerrero-Flores A, Rodríguez-Sánchez R, y col. Riesgo cardiovascular en pacientes con VIH. Med Int Mex 2008;24:284-288.

10. Alvarez-Cosmea A, López-Fernández V, Prieto-Díaz MA, Díaz-González L, y col. Procam y Framingham por categorías: ¿miden igual riesgo? Medifam 2002;12:260-265.

11. World Health Organization. Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. www.who.int./cardiovascular.../PocketGL.English.AFR-D-E.rev1.pdf

12. Knobel H, Jericó C, Montero M, Sorli ML, et al. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk Equations (Framingham, SCORE, and PROCAM). Aids Patient Care and STDs 2007;21:452-457.

13. Pita-Fernández S, Pértegas-Diaz S. La fiabilidad de las mediciones clínicas: el análisis de concordancia para variables numéricas. http://www.fisterra.com/mbe/investiga/conc_numerica/conc_numerica.pdf

14. De Socio GV, Martinelli L, Morosi S, Fiorio M, et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scan J Infect Dis 2007;39:805-812.

15. Hadigan C, Meigs JB, Wilson PWF, D’Agostino RB, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-916.

16. Contreras-Solís RE, Rendón-Aguilar P, Tufiño-Olivares ME, Levario-Carrillo M, Uranga-Urías TM. Factores de riesgo cardiovascular en población adulta de la Unidad de Medicina Familiar de Meoqui, Chih. Rev Mex Cardiol 2008;19:7-15.

17. Fornasini M, Brotons C, Sellare J, Martinez M, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Family Practice 2006;23:28-33.

18. Medina Lezama J, Chirinos Medina J, Zea Díaz H, Morey Vargas O, y col. Estimaciones del riesgo cardiovascular global en la población adulta de Arequipa metropolitana: Resultados del estudio PREVENCION. Revista Peruana de Cardiología 2006;32:129-144.

19. Guzmán Padilla S, Roselló Araya M. Riesgo cardiovascular global en la población adulta del área urbana del Cantón Central de Cartago, Costa Rica. Rev Costarr Cardiol 2006;8:11-17.